

UK Reviews Dronedarone Use for Atrial Fibrillation

The use of the antiarrhythmic drug produced by Sanofi-Aventis was discouraged by NICE in December on the grounds that it was more expensive and not as effective as others in the market. UK cardiologists, nurses, patients and industry are now encouraging it to be made available for prescription by the National Health Service (NHS).

Already discussed in Parliament, comments from interested parties are being reviewed and a stakeholder inquiry is underway. Efforts have been coordinated by the Atrial Fibrillation Association and Heart Rhythm UK with more than 100 doctors already on the petition.

A final guidance to the NHS will be issued by NICE in the weeks following their second panel meeting, currently scheduled for 24 February.

Published on : Tue, 9 Feb 2010